Enhance your practice with CME and tools that focus on diseases and conditions impacting the female patient.
Ongoing Trials in Oral Targeted Strategies in Breast Cancer
Aditya Bardia, MD, MPH, FASCO
22nd Annual Women’s Health Annual Visit (WHAV)
December 04, 2026
New York, New York
Escalate With Intention: Stepwise, Target-Anchored Moves
Christyn Edmundson, MD
Gil I. Wolfe MD, FAAN
Shared Goals, Shared Gains: Align With Patient Preferences
Minimal By Design: Define MSE Endpoints
The 2-Point Signal: Apply ≥2-Point Rule
Treat. Target. Transform: Applying Treat-to-Target Principles in the Management of Generalized Myasthenia Gravis (gMG)
Scorecards That Matter: Use MG-ADL, MG-MMT, QMG, QoL
From Abstract to Action in Breast Cancer: Interpreting Recent Data on Oral SERDs and Endocrine Targeting Strategies
Erica L. Mayer, MD, MPH
Rapid Data Pulses From ASCO 2026: Emerging Data on Oral Targeted Strategies in Breast Cancer
FcRn: Same Class, Different Paths—Spot Agent Differentiators
Target Locked in gMG: Why T2T Matters
Precision Starts Before Birth: Reimagining Fetal Care Through FcRn Immune Modulation
Kenneth J. Moise Jr., MD
Kara B. Markham, MD
Not Just a Headache: Migraine Across Women’s Lifespan
Jelena Pavlović, MD, PhD
Amaal J. Starling, MD, FAHS, FAAN
ENDOVOICE Live: Endometriosis—A Chronic Burden of Reproductive Years
Linda Bradley, MD
Obianuju Sandra Madueke-Laveaux, MD, MPH
Lauren R. Kornegay
Diagnosing and Treating IBS: It Begins With One Simple Question
Brooks D. Cash, MD, AGAF, FACG, FACP, FASGE
Kimberly D. Orleck, PA-C
SERENA-6: Acting on ESR1 Mutations in Advanced Breast Cancer
November 13, 2026
Pasadena, California
Turning Flares Into Function: Flag Uncontrolled Disease
When to Begin FcRn: Initiation Criteria, Key Evidence
Fetal and Neonatal Alloimmune Thrombocytopenia (FNAIT): Overcoming Diagnostic and Therapeutic Challenges
Karin J. Blakemore, MD
Emilie L. Vander Haar
Can We Talk? Optimizing Patient Buy-In to the Management of Endometriosis
Lee P. Shulman, MD, FACMG, FACOG
Clinical Considerations for the Diagnosis of Endometriosis
James A. Simon, MD, CCD, NCMP, IF, FACOG
Pre- and Postoperative Use of GnRH Antagonists
Ayman Al-Hendy, MD, PhD, FRCSC, FACOG, CCRP
ELEVATE: Elacestrant Plus Capivasertib in Advanced Breast Cancer
Primary Biliary Cholangitis: Shining Light on an "Invisible" Female Health Burden
Gideon Hirschfield, MB, BChir, PhD
Marlyn Mayo, MD
Women’s Sleep Health – Addressing Gaps in OSA Diagnosis and Treatment Across Life Stages
Alison Kole, MD, MPH, FACCP
Ghada Bourjeily, MD, FCCP
Rashmi Nisha Aurora, MD
Audrey Wells, MD
Early Diagnosis: Its Pivotal Role in Optimizing Outcomes in Patients With Endometriosis – Psychosocial and Physical Consequences
Samantha Denäe
Capturing the Impact of Endometriosis on Health-Related QoL: The Role of Patient Questionnaires
The Integral Role of GnRH Antagonists in the Management of Endometriosis
Sawsan As-Sanie, MD
Changing the Paradigm in the Management of Endometriosis: Moving Away From “Surgery First” to “Pharmacologic Therapy First”
Cut to the Chase: Why Not Treat Endometriosis With GnRH Antagonists First?
Loading...
We're glad to see you're enjoying Omnia Education… but how about a more personalized experience?
Press cancel to remain on Omnia Education. Press the link below or the continue button to keep going.